CBO at clinical-stage precision oncology company, leading corporate development activities including investor & public relations, business development, competitive intelligence, portfolio / pipeline strategy, and new product planning.

Founded a life sciences consultancy and advised multiple emerging biopharma organizations on matters of commercial, portfolio, and corporate strategy & tactics.

Built and oversaw the Loxo Oncology commercial organization, with broad responsibilities across Marketing, Market Access, Trade/Distribution, Commercial Insights & Analytics, Operations, and Field Force.Led the launch of VITRAKVI (larotrectinib), in co-promote partnership with Bayer, as well as all commercialization activities for LOXO-292.

Responsible for global commercial strategy and global marketing activities across the Pfizer Oncology hematologic malignancies therapeutic portfolio. Assets / indications include:• Bosulif (bosutinib) – chronic myelogenous leukemia (CML)• Mylotarg (gemtuzumab ozogamicin) – antibody drug conjugate targeting CD33, global launch for acute myelogenous leukemia (AML)• Inotuzumab ozogamicin – antibody drug conjugate targeting CD22, global launch for acute lymphoblastic leukemia (ALL)• Glasdegib – novel small-molecule inhibitor of Smoothened (SMO), in clinical development for hematologic malignancies

US Marketing Lead for the Pfizer Renal Cell Carcinoma (RCC) therapy franchise (SUTENT, TORISEL, and INLYTA)

US Marketing Team Lead for INLYTA.

Chief of Staff position for the President, North America of Pfizer Specialty Care. Responsibilities include operations management, strategic support, and special projects for President and North America Leadership Team.

Member of US commercial launch team for XALKORI (crizotinib), a first-in-class companion diagnostic-targeted therapy for the treatment of advanced ALK+ non-small cell lung cancer (NSCLC). Responsibilities include brand development (messaging, creative, etc.), digital/multichannel marketing, PR activities, and sales force configuration and training.Prior: US commercial launch lead for SUTENT in pancreatic neuroendocrine tumor (NET).

Managed all US in-line marketing activities for SUTENT in gastrointestinal stromal tumor (GIST).

Conducted global pre-launch marketing activities for late-stage melanoma drug.

Managed market research, forecasting, and sales analytics for two in-line products, VELCADE (multiple myeloma), and INTEGRILIN (acute coronary syndromes).

Entrepreneurial experience supporting CEO of drug development start-up included: development of financing strategy, business plan, and company website. Solicited technologies for in-licensing and performed due diligence.

Management consulting experience for private/public biopharmaceutical and healthcare VC clients. Casework included diagnostic and therapeutic business strategy, product portfolio optimization, and new market assessment.